**This release will continue to be updated as more Press Program details are finalized.

ALEXANDRIA, Va. – The global oncology community will gather in Chicago to share and discuss the latest clinical cancer research impacting patient care at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Treatment advances involving targeted therapies, immunotherapy, and new uses of technology, as well as research on improving patient quality of life and outcomes are among the topics that will be highlighted in the meeting’s official Press Program.  

The 2024 ASCO Annual Meeting will take place May 31-June 4 in Chicago and online. The theme of this year’s conference is The Art and Science of Cancer Care: From Comfort to Cure. 

This year, ASCO received a record number of abstract submissions and as a result more than 5,000 abstracts will be presented or published as part of the 2024 ASCO Annual Meeting. ASCO will publish the regular abstracts on Thursday, May 23, at 5:00 PM (ET) on asco.org/abstracts. Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released at 7:00 AM (CT)/8:00 AM (ET) on their day of scientific presentation at the Meeting. The complete embargo schedule is available online. 

EMBARGOED PRE-MEETING PRESS BRIEFING (VIRTUAL EVENT) – Thursday, May 23, 12:00-1:30 PM (ET)

In advance of the release of regular abstracts on May 23, an embargoed, virtual press briefing for credentialed media will be held earlier the same day and will highlight four abstracts. The embargo will lift on May 23 at 5:00 PM (ET) for the following studies:

• Using artificial intelligence to re-engage communities of color who have missed colonoscopy appointments (Abstract 100) 
• A prospective study examining long-term fertility outcomes among younger breast cancer survivors. (Abstract 1518)
• Impact of HPV vaccination on cancer rates beyond cervical cancer, among both men and women (Abstract 10507)
• Long-term follow-up from the Women’s Health Initiative randomized trials examining menopausal hormone therapy and ovarian and endometrial cancers (Abstract 10506)

EMBARGOED PRE-MEETING PRESS BRIEFING (VIRTUAL EVENT) – Wednesday, May 29, 9:30-11:00 AM (ET)

Several Late-Breaking Abstracts (LBAs) being presented on Friday, May 31 and Saturday, June 1 at the meeting, will be discussed in an embargoed, virtual press briefing for credentialed media on May 29:

• Five-year survival and safety outcomes from the phase III CROWN study comparing lorlatinib to crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer. (Abstract LBA8503) 
  Embargo lifts Friday, May 31 at 7:00 AM (CT)/8:00 AM (ET) 
• The primary results from the ASC4FIRST study, a randomized phase III trial looking at asciminib compared to investigator-selected tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia. (Abstract LBA6500) 
  Embargo lifts Friday, May 31 at 7:00 AM (CT)/8:00 AM (ET)
• Results from the phase III GHSG HD21 study, examining tolerability and efficacy of BrECADD compared to BEACOPP in advanced stage classical Hodgkin lymphoma. (Abstract LBA7000)
  Embargo lifts Saturday, June 1 at 7:00 AM (CT)/8:00 AM (ET) 

RESEARCH TO BE RELEASED DURING THE ANNUAL MEETING 

During the Annual Meeting, two press briefings will be held on Saturday, June 1: one from 8:00-9:15 AM (CT) highlighting research from ASCO’s Plenary Session and one from 12:30-1:30 PM (CT) highlighting additional LBAs that will be presented during the meeting. The press briefings will be held in person and livestreamed for credentialed reporters covering the meeting remotely.

LBAs that will be featured in these press briefings include:

• The prospective phase III ESOPEC trial comparing perioperative chemotherapy to neoadjuvant chemoradiation in patients with esophageal cancer. (Plenary, Abstract LBA1) 
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET)  
• The phase III NADINA trial studying neoadjuvant nivolumab plus ipilimumab compared to adjuvant nivolumab in melanoma. (Plenary, Abstract LBA2) 
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET) 
• Trial evaluating the effectiveness of early palliative care delivered via telehealth compared to in-person for patients with advanced lung cancer. (Plenary, Abstract LBA3) 
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET) 
• Primary results of the phase 3 LAURA study examining osimertinib after chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer. (Plenary, Abstract LBA4)
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET)  
• The phase III ADRIATIC study evaluating durvalumab with or without tremelimumab in patients with limited-stage small-cell lung cancer. (Plenary, LBA5)
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET)  
• The randomized phase III DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone compared to pomalidomide plus bortezomib and dexamethasone in relapsed or refractory multiple myeloma. (Abstract LBA105)
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET)  
• The CARACO phase III randomized trial, studying the omission of lymphadenectomy in patients with advanced ovarian cancer treated with cytoreductive surgery after neoadjuvant chemotherapy. (Abstract LBA5505) 
  Embargo lifts Sunday, June 2 at 7:00 AM (CT)/8:00 AM (ET) 
• Lessons from a prospective trial examining treatment-induced neuropathy in Black women with breast cancer (Abstract 503) 
  Embargo lifts Monday, June 3 at 7:00 AM (CT)/8:00 AM (ET)  

All press briefings will also be recorded and made available to credentialed reporters in ASCO’s Media Headquarters.

ADDITIONAL STUDIES OF NOTE

The following studies will be included in the official ASCO Tip Sheet, a brief summary of additional noteworthy research. The Tip Sheet will be sent to credentialed reporters ahead of the meeting and will include additional comments from the lead authors and ASCO experts.

The embargo will lift Thursday, May 23 at 5:00 PM (ET) for the following studies:  

• Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial. (Abstract 587)
• Trends in human papilloma virus vaccination uptake by sex and race/ethnicity among US adolescents and young adults, 2011-2020. (Abstract 10519)
• Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). (Abstract 7500)
• Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET). (Abstract 3500)
• A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC). (Abstract 5010).
• Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results. (Abstract 10016).
• Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial. (Abstract 108).
• The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial. (Abstract 107).
• Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. (Abstract 104)
• Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma. (Abstract 2004)
• First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. (Abstract 1003).
• Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. (Abstract 4506)
• Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer. (Abstract 12000)
• A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186. (Abstract 4003)

The embargo will lift Friday, May 31 at 7:00 AM (CT)/8:00 AM (ET) for the following study:

• Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. (Abstract LBA8505)

The embargo will lift Saturday, June 1 at 7:00 AM (CT)/8:00 AM (ET) for the following studies:

• KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS^G12C mutation. (LBA8509)
• Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial (LBA1001)

The embargo will lift Monday, June 3 at 7:00 AM (CT)/8:00 AM (ET) for the following studies:

• Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. (Abstract LBA3512)
• IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). (LBA8035)

MEDIA RESOURCES 

Media registration: To participate in the Annual Meeting press briefings and/or register to attend the Meeting in person in Chicago, please visit ASCO’s Media Headquarters at https://profile.asco.org/media/workflow. Step-by-step instructions are available online. 

Requests for media credentials must be submitted in Media Headquarters no later than Wednesday, May 15, to participate in the pre-meeting press briefing on May 23. Pre-registration is required for on-site attendance and must also be requested by this date. 

Annual Meeting Media Resource Center: Visit asco.org/AMMRC for press releases, the press briefing schedule, embargo policies, high-resolution photos, and the Virtual Press Room (an online repository of corporate and institutional press materials from third-party organizations).  

###